Avalon GloboCare to Participate in the 35th Annual Roth Conference
March 03, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy...
Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
February 13, 2023 09:00 ET
|
Avalon GloboCare Corp.
Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement Adds Strong Clinical Synergies to Existing Avalon Portfolio Marks Launch of New Roll-Up Strategy Targeting...
Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
January 17, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and...
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
January 11, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics...
Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
January 03, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics...
Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
December 14, 2022 09:00 ET
|
Avalon GloboCare Corp.
Newly issued preferred stock convertible at a minimum of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Laboratory Services acquisition expected to close within 30...
Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
December 12, 2022 09:00 ET
|
Avalon GloboCare Corp.
Company Discontinues China Operations, Reducing Cash Burn Encourages Shareholders to Vote in the Upcoming Annual Shareholder Meeting on December 29th FREEHOLD, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE)...
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
November 09, 2022 16:00 ET
|
Avalon GloboCare Corp.
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 ...
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
November 08, 2022 09:10 ET
|
Avalon GloboCare Corp.
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and...
Avalon GloboCare Receives Allowance for Joint U.S. Patent
September 29, 2022 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update...